TTT-therapy Targeting Acute Leukemia with TdT-TCR-T-cell therapy
- Coordinator
- Oslo Universitetssykehus Hf, Norway
- Runs
- 1 October 2023 to 31 March 2025
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101123138
What the project is doing
In the project's own words, from its summary on CORDIS.
The aim of this PoC project is to commercialize new therapy for acute lymphoblastic leukemia (ALL) developed in context of my ERC consolidator grant. T-cell receptors (TCRs) have in recent years emerged as promising therapeutic molecules in cell- and gene-therapy of cancer. I have completed the pre-clinical validation of a TCR that recognizes an HLA-bound peptide from a novel target, the nuclear enzyme terminal deoxynucleotidyl transferase (TdT-TCR).
In vitro and in vivo data from four different mouse models show eradication of ALL and no indications of toxicity. T-cells genetically modified with the TdT-TCR effectively kill lymphoblastic cancer cells while sparing healthy B and T-cells, myeloid cells and hematopoietic stem cells. Funding has been secured for an investigator-initiated trial to determine safety and explore efficacy of TdT-TCR-T-cell therapy – TTT-therapy.
The trial will recruit ALL patients relapsing from/refractory to standard therapy, who have a dismal prognosis and thus a great unmet medical need. To facilitate commercial development, I have created a start-up company and secured the company exclusive licenses for the patents on the TdT-TCR and the technology used for the development, on which I am the main inventor. In the proposed ERC PoC project, I and my strong team of advisers with expertise in the business development, clinical development, IPR and financial aspects needed for commercialization, will conduct a market analysis for TTT-therapy and develop an IPR and business strategy for the start-up company.
Since several studies report expression of TdT in acute myeloid leukemia (AML), I will conduct laboratory research to determine if the TdT-TCR can also mediate killing of AML cells. AML patients have an overall 5-year survival of only 30% and hence a great medical need that potentially could be met by TTT-therapy. The described work has the potential to contribute to saving lives that would otherwise be lost to acute leukemia.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Oslo Universitetssykehus Hf | Oslo | Norway | Coordinator |
| Trx Therapeutics AS | Eiksmarka | Norway | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI